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Abstract:
Introduction: This study aimed to review the prevalence of NMS in patients with Parkinson’s disease 
in Split-Dalmatia County and to investigate the effects of other variables on the number and structure 
of NMS.
Materials and Methods: This observational cross-sectional pilot study was conducted at the Depart-
ment of Neurology, University Hospital of Split. This study lasted from November 2017. to April 
2018. and it included 31 patients, hospitalized or treated in the infirmary at the Department of 
Neurology. By examining medical documentation we acquired necessary demographic and medical 
information about our subjects. Subjects were then examined and subjected to filling out Parkinson’s 
disease-specific questionnaires: NMSQuest, Hoehn&Yahr scale, UPDRS, and Schwab&England scale. 
To analyze given variables we used the Mann-Whitney U test, Kruskal-Wallis test, Spearman’s coeffi-
cient of correlation, and ꭓ2 test.
Results: On average 12 dwifferent NMS were reported per patient. Most prevalent NMS were re-
ported to be nocturia (67.74%), urinary urgency (61.29%), constipation (61.29%), intense dreams 
(58.06%), and forgetfulness (58.06%). The least prevalent NMS reported were delusions (6.45%), 
hallucinations (16.12%), and daytime sleepiness (25.80%). There were neither statistical differences 
in the total number of NMS nor in demographic variables between men and women. The increased 
burden of NMS correlated with the disease duration. Prevalence of depression, anxiety, and miscel-
laneous symptoms rose with the length of disease duration. We established a connection between the 
number of NMS and the stage of disease according to Hoehn and Yahr. Patients in higher stages of 
disease (moderate and severe) reported more severe NMS burden than patients in the mild stage of 
the disease, while patients in the moderate stage had the largest NMS score of all groups. Patients in 
the mild stage reported urinary, also digestive, and cognitive symptoms, in the moderate stage urinary 
symptoms, sexual dysfunction, and cardiovascular symptoms were most reported, while in the severe 
stage of the disease, patients reported cardiovascular symptoms, depression, and anxiety alongside 
urinary symptoms as most prevalent.
Conclusions: Patients are most affected by the autonomic spectrum of NMS, especially urinary symp-
toms. Duration of the disease and stage of the disease are proven to affect the total number of NMS, 
while age at onset, current age, and sex have been disproven to have any effect on the total NMS score. 
Patients in the moderate stage reported the most NMS.
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Sažetak:
Učestalost nemotoričkih simptoma u bolesnika s Parkinosnovom bolesti u Splitsko-dalmatinskoj 
županiji
Uvod: Cilj ove studije bio je istražiti učestalost NMS-a u bolesnika oboljelih od Parkinsonove bolesti u 
Splitsko-dalmatinskoj županiji te učinke ostalih varijabli na broj i strukturu NMS-a.
Materijali i metode: Ova opisno presječna pilot studija provedena je na Klinici za neurologiju, Kli-
ničkog bolničkog centra Split. U studiji koja je trajala od studenog 2017. do travnja 2018. sudjelovao 
je 31 bolesnik, hospitaliziran ili liječen u ambulanti na Klinici za neurologiju. Uvidom u medicinsku 
dokumentaciju prikupili smo potrebne demografske i medicinske podatke o našim ispitanicima. 
Ispitanici su zatim pregledani i podvrgnuti popunjavanju upitnika specifičnih za Parkinsonovu bolest: 
NMSQuest, skala Hoehn & Yahr, UPDRS i skala Schwab & England. U statističkoj obradi podataka 
koristili smo Mann-Whitney U test, Kruskal-Wallisov test, Spearmanov koeficijent korelacije i ꭓ2 test.
Rezultati: U prosjeku 12 različitih NMS-a je prijavljeno po ispitaniku. Najzastupljeniji pojedinačno 
prijavljeni NMS bili su nokturija (67,74%), urinarna inkontinencija (61,29%), konstipacija (61,29%), 
intenzivni snovi (58,06%) i zaboravljivost (58,06%). Najrjeđe prijavljeni NMS-i bili su deluzije 
(6,45%), halucinacije (16,12%) i dnevna pospanost (25,80%). Između muškaraca i žena nismo usta-
novili statistički značajne razlike u ukupnom broju NMS-a, niti u demografskim značajkama bolesti. 
Porast duljine trajanja bolesti korelirao je s porastom opterećenja NMS-a. Depresija, anksioznost i 
simptomi domene razno značajno rastu s porastom duljine trajanja bolesti. Ustanovili smo povezanost 
broja NMS-a sa stadijem bolesti po Hoehn i Yahru. Bolesnici u većim stadijima (srednji i teški) bolesti 
imali su više NMS-a, s tim da su bolesnici srednjeg stadija bolesti u našem istraživanju imali najviše 
NMS-a. Kroz sve stadije bolesti simptomi mokrenja najviše opterećuju bolesnike. U blagom stadiju 
bolesti ispitanike uz mokrenje opterećuju simptomi probave i kognicije, u srednjem stadiju problemi 
spolnog odnosa i kardiovaskularni problemi, a u teškom stadiju bolesti uz kardiovaskularne probleme, 
depresija i anksioznost.
Zaključci: Bolesnike najviše opterećuje autonomni spektar NMS-a, posebno simptomi mokraćnog su-
stava. Na ukupni broj NMS-a utječe duljina trajanja bolesti i stadij bolesti, a ne utječe dob postavljanja 
dijagnoze, trenutna dob i spol. Bolesnici srednjeg stadija bolesti prijavili su najviše NMS-a.
Ključne riječi: Parkinsonova bolest, Nemotorički simptomi, upitnik
Introduction
In 1817. James Parkinson recognized the importance of mo-
tor symptoms of then called „shaking palsy“ and identified key 
non-motor symptoms, such as autonomic dysfunction, disorders 
of sleep, cognitive and neuropsychiatric symptoms 1. Today, two 
hundred years later, the nonmotor symptoms (NMS) of PD are 
still often overlooked. A prospective study involving 101 patients 
found that neurologists do not discuss serious symptoms such 
as depression, anxiety, fatigue, and sleep disturbance with more 
than 50% of patients. These results may be due to the limited 
time spent with the patient, the misperception of the patient or 
caregiver that their symptoms are not related to the disease, or 
the lack of awareness of physicians who then direct the conver-
sation toward motor symptoms. In addition to neurologists, 
an international study conducted in 2010 found that 62% of 
patients did not report symptoms such as apathy, pain, sexual 
dysfunction, sleep disorders, and stool incontinence because they 
were uncomfortable or unaware that these symptoms were asso-
ciated with PD. It is for these reasons that questionnaires such as 
the Non-Motor Symptoms Questionnaire (NMSQuest) and the 
Non-Motor Symptoms Scale (NMSS) have recently been devel-
oped to help clinicians quantify the overall burden of nonmotor 
symptoms and their impact on the quality of life. NMSQuest is 
a questionnaire that contains thirty most common non-motor 
symptoms and the patient answers each of them with “yes” or 
“no”. It is designed to help patients flag certain symptoms that 
they find troublesome but often overlook when visiting their 
neurologist, and to assist the busy clinician in steering the exami-
nation and history taking in the right direction 2,3. 
Parkinson’s disease can be divided into the preclinical phase (sup-
ported by molecular and imaging markers), the premotor phase 
(with early non-motor symptoms), and the motor phase, which 
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is the “tip of the iceberg”. Also, some non-motor symptoms 
dominate in the early or premotor phase (hyposmia, constipa-
tion), others are present during the entire duration of the disease 
(fatigue, pain), and others occur especially in the advanced stage 
of the disease (dementia, apathy, autonomic dysfunction). As 
the average life expectancy and life expectancy of the population 
increase, non-motor symptoms become increasingly important. 
The impact of nonmotor symptoms on quality of life has been 
proven to be crucial in numerous studies and if left untreated 
causes a significant decline in quality of life, hospitalization, and 
institutionalization which increases the cost of therapy fourfold. 
Also, nonmotor symptoms are useful biological markers in the 
diagnosis of PB. A study conducted in Germany comparing un-
treated patients with PD and a control group showed that diag-
nostic agents such as NMSQuest and SCOPA-autonomic (scale 
of autonomic symptoms) combined with laboratory tests such as 
the odor identification test achieve sensitivity and specificity ( > 
0.9) adequate for a biological marker of PD development 2,3.
Materials and methods
This was an observational cross sectional pilot study. It was 
conducted at the Department of Neurology, University Hospital 
Center Split. This study was in accordance with Ethics com-
mittee of University Clinical Hospital Split and all participants 
provided written informed consent according to the Declara-
tion of Helsinki. We recruited 31 PD patients who were seen 
in Department of Neurology, University Clinical Hospital Split 
between December 2017. and April 2018. All participants met 
UK PD Society Brain Bank Clinical Diagnostic Criteria for PD. 
Exclusion criteria included patients with atypical and secondary 
PD, such as MSA.
Questioning of patients would start with the taking of routine 
demographic data (age, gender, etc.) and collecting information 
about their medical history. Afterwards patients would be exam-
ined by the movement disorder specialist and administered ques-
tionnaires which they had to fulfill. Questionnaires we used in 
our study were UPDRS, NMSQuest (Non – Motor Symptoms 
Questionnaire), Hoehn&Yahr scale, and Schwab&England scale. 
For this purpose NMSQuest was translated to Croatian with 
permission from holders of author rights International Parkinson 
and Movement Disorder Society (MDS). NMSQuest is envi-
sioned to be a self completed screening tool in which patients 
themselves or with the help from caregiver answer thirty ques-
tions representing NMS with „Yes“ or „No“ in case they have felt 
one of those symptoms in the last thirty days. Thirty individual 
NMS are then divided in nine different domains: seven NMS 
fall in „Digestion“ domain, two in „Urinary“, three „Cognition“, 
two “Hallucination/Delusion“, two „Depression/Anxiety“, two 
„Sexual function“, two „Cardiovascular“, five „Sleep disorder“, 
and five „Miscellaneous“ (unexplained pain, weight change, fall-
ing, sweating, diplopia). Prevalence of each NMS was calculated 
by adding the number of positive answers and transforming 
it to a percentage. To examine the number of NMS in differ-
ent groups and domains we quantified the number of positive 
answers for each patient, group, domain (men – women, patients 
younger/older than 70 years, etc.) transformed them to median 
or percentage and compared them to each other. 
UPDRS (Unified Parkinson’s disease rating scale) is a stand-
ard scale used to follow the progression of PD during clinical 
examinations. It contains in it non motor symptoms, motor 
symptoms, and treatment side effects. For quantifying results of 
UPDRS we used internet UPDRS calculator farmacologiaclinica.
info. Schwab&England scale is a standardized daily activities 
scale for PD patients. It is used to asses the percentage of daily 
activities in which PD patients participate, and the need for ad-
ditional support. It is measured in percentages with 100% mean-
ing total independence of patients, and 0% meaning patients 
are bed ridden, and his/her vegetative functions are failing. After 
complete neurologic assessment patients were divided in different 
stages of disease according to Hoehn&Yahr scale. With 1-2,5 
stages being mild, stage 3 being moderate, and stages 4 and 5 
being severe. All questionnaires except NMSQuest were previ-
ously translated to Croatian. Data analytics were done using a 
statistical software IBM SPSS Statistics version 20, 2011. ( New 
York, USA). We interpreted results with P<0,05 as significant, 
and in comparing different groups, and domains and associations 
between them used Mann – Whitney U test, Kruskal – Wallis 
test, Spearman coefficient of correlation, and ꭓ2 test. Spearman 
coefficient of correlation <0,3 presented insignificant correlation; 
from 0,3 to 0,59 presented slight correlation, >=0,6 presented 
significant correlation, and >=0,7 presented very significant cor-
relation of researched data.
Results
In our pilot study there were 31 patients with PD treated in 
University Hospital Center Split. Examination and fulfillment of 
questionnaires took place from November 2017. till April 2018. 
Of all patients 14 (45%) were women, and 17 (55%) were men. 
Median of age at which diagnosis was made was 59 years (Q1-
Q3:52-66;min.-max.:41-83). Median of the duration of disease 
was 8 years (Q1-Q3:5-15;min.-max.:1-24). Median of age dur-
ing examination was 70 years (Q1-Q3:64-75;min.-max.:46-85). 
As seen from Table 1. there was no significant statistical differ-
ence between men and women concerning these variables. 
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Table 1. Age when disease was diagnosed, duration of disease, age at examination in relation to gender






Age at diagnosis 56(53-65;41-83) 62,5 (52-66;46-72) 0,382
Duration of disease 8 (5-13;2-17) 8,5 (6,5-15;1-24) 0,369
Age at examination 65 (62-72;46-85) 71 (66-77;58-83) 0,136
*Mann – Whitney U test
From the total number of patients 17 (55%) were in mild stage 
of the disease (according to Hoeh&Yahr scale), 5 (16%) were 
in moderate stage, and 9 (29%) were in severe stage. Median of 
total NMS was 12 (Q1-Q3:8-16;min.-max.:1-26). In average 
patients reported 12 different NMS (12±6). All patients had at 
least one NMS, while one patient reported whooping 26 NMS 
from possible 30. Percentage of individual NMS according to 
data collected from NMSQ are shown in Table 2. 
We then divided patients in to groups according to the median of 
age at diagnosis (59), median of duration of disease 8, median of 
age at examination (70), and according to the stage of the disease. 
Results we got from data analysis of these groups is shown in 
Table 3. There was no statistically significant difference in results 
of NMSQuest between men and women (Z=0,875; P=0,381), 
between those patients that were diagnosed with PD before or af-
ter their 59th year (Z=0,139;P=0,890), and between those patient 
that were younger or older than 70 years (Z=0,951;P=0,342). 
We proved statistically significant difference in NMSQuest 
results between patients with the duration of disease less than 
8 years and those in which disease lasted longer than 8 years 
(Z=2,4;P=0,017). Patients with longer lasting disease had scored 
5 more NMS than patients who had shorter lasting disease. We 
found statistically significant association of NMSQuest results 
with the stage of disease (H&Y) (ꭓ2=11,8; P=0,003). Both 
patients in moderate (P=0,021) and severe stage (P=0,015) had 
significant difference in NMSQuest scores compared to patients 
in mild stage. Median of NMS for moderate stage patients was 
larger for 9 points in comparison to patients with mild stage. 
Median of NMS for severe stage patients was larger for 7 points 
compared to patients in mild stage. NMSQuest has nine domains 
and using Spearman coefficient of correlation we found statisti-
cal significant association between certain domains. Digestive 
symptoms domain has mild association with urinary symptoms 
domain (ρ=0,356; P=0,049) with cognitive symptoms domain 
(ρ=0,457; P=0,010), and with hallucination domain (ρ=0,412; 
P=0,021), and significant association with sleep disorders domain 
(ρ=0,638; P<0,001), and miscellaneous domain (ρ=0,621; 
P<0,001). Urinary domain has slight association with sleep disor-
ders domain (ρ=0,412; P=0,021). Cognitive symptoms domain 
has slight association with sexual function (ρ=0,383; P=0,034), 
hallucinations (ρ=0,466; P=0,008) and miscellaneous domain 
(ρ=0,363; P=0,045). Depression and anxiety has almost signifi-
cant association with miscellaneous (ρ=0,597; P<0,001). Sleep 
disorders has slight association with cardiovascular (ρ=0,517; 
P=0,003) and with miscellaneous domain (ρ=0,516; P=0,003).
Linear association of NMS with duration of disease in our 
patients was statistically significant for depression/anxiety 
(ρ=0,660) and miscellaneous domain (ρ=0,425). We found sta-
tistically significant association of NMS total score with duration 
of disease (Table 4.).
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Table 2. Percentage of individual NMS
NMS N=31 %
Dribbling 15 48,38
Loss of taste/smelling 14 45,16
Swallowing difficulties 13 41,93
Vomiting 9 29,03
Constipation 19 61,29
Bowel incontinence 9 29,03
Incomplete bowel emptying 15 48,38
Urgency 19 61,29
Nocturia 21 67,74
Unexplained pain 12 38,70
Weight change 9 29,03
Forgetfulness, memory 18 58,06
Loss of interest 13 41,93
Hallucinations 5 16,12
Problems concentrating 11 35,48
Depression 13 41,93
Anxiety 12 38,70
Sex drive 15 48,38
Sex difficulty 10 32,25
Vertigo 17 54,83
Falling 9 29,03
Daily sleepiness 8 25,80
Insomnia 10 32,25
Intense dreams 18 58,06
Acting out during dreams 15 48,38
Restless legs 15 48,38
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Table 3. Comparison of NMS between different patient groups
Median (Q1-Q3;min.-max.)







































*Mann-Whitney U Test †Kruskall-Wallis Test
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Table 4. Spearman coefficient of correlation between duration of PD, NMS total score, and NMS domains
NMS Domain ρ (P)
Duration of PD with NMS
NMS Total score 0,475 (0,007)
NMS Digestion 0,223 (0,138)
NMS Urinary 0,272 (0,138)
NMS Cognition 0,336 (0,064)
NMS Depression/Anxiety 0,660 (0,009)
NMS Sexual function 0,182 (0,327)
NMS Cardiovascular 0,225 (0,166)
NMS Hallucinations -0,117 (0,524)
NMS Sleep disorders 0,303 (0,097)
NMS Miscellaneous 0,425 (0,017)
When comparing domains of NMSQuest with stages of disease 
according to H&Y we found that the patients in mild stage of 
disease are mostly bothered by the symptoms of urinary (47%), 
cognitive (37%), and digestive dysfunction (34%). Patients in 
moderate stage complained the most on urinary (90%), sexual 
function (70%), and cardiovascular symptoms (70%). Patients in 
severe stage were complaining on urinary (83%), cardiovascular 
(83%), and depression and anxiety (67%) (Table 5.).  
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Table 5. NMS points in domains compared amongst different stages of PD
                 NMS points
Max. Points made
(%)
Max. Points made (%) Max. Points made (%)
Domain Stage of disease
Mild (n=17) Moderate (n=5) Severe (n=9)
Digestion 0-7  119 40 (34%) 35 22 (63%) 63 32 (51%)
Urinary 0-2   34 16 (47%) 10  9 (90%) 18 15 (83%)
Cognitive 0-3   51 19 (37%) 15  8 (53%) 27 15 (56%)
Hallucination 0-2   34  3 (9%) 10  0 (0%) 18  4 (22%)
Dep./Anx. 0-2   34  7 (28%) 10  6 (60%) 18 12 (67%)
Sexual 0-2   34 10 (29%) 10  7 (70%) 18  8 (44%)
Cardiovascular 0-2   34  9 (26%) 10  7 (70%) 18 15 (83%)
Sleep 0-5   85 24 (28%) 25 16 (64%) 45 20 (44%)
Miscallaneous 0-5   85 20 (24%) 25  9 (36%) 45 22 (49%)
Legend: Max. is the maximum possible number of positive answers for each group ( for example in mild stage disease with 17 patients if all scored 7 in digestive domain, 
total score would be 119; for urinary domain which has 2 questions total score would be 34). Points made is the sum of points scored by the patients of each stage. Ab-
breviations: Dep.- depression, Anx.- anxiety.
We found statistically significant differences of domain results 
amongst stages of PD with digestive domain (χ2=6,9; P=0,032) 
(difference being made by patients in moderate stage com-
pared to mild (P=0,043), urinary (χ2=6,9; P=0,032) (moderate 
stage compared to mild (P=0,05), and sever compared to mild 
(P=0,05), depression and anxiety (χ2=7,2;P=0,027) (severe com-
pared to mild stage (P=0,037), cardiovascular domain (χ2=12,8; 
P=0,002) (severe compared to mild (P=0,002)), and sleep 
dysfunction domain (χ2=6,9; P=0,031) (moderate compared to 
mild (P=0,037)). (Table 5.).
We didn’t find statistically significant difference of domain results 
between stages for cognitive domain (χ2=2,3; P=0,314), hallu-
cinations (χ2=1,3; P=0,507), sexual function (χ2=3,4; P=0,179) 
and miscellaneous (χ2=4,9; P=0,084) (Table 5.). All used 
questionnaires had statistically significant high and very high 
correlation between them (P<0,001) (Table 6.) Total results of 
NMSQuest had significant correlation with total UPDRS score, 
and percentage of daily activities disability (Table 6.). 
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Table 6. Spearman coefficient correlation (ρ)(P) between questionnaires.
ρ (P)











All questionnaires were significantly associated with the duration of PD: Hoehn&Yahr ρ=0,391 (P=0,029), UPDRS ρ=0,456 (P=0,010), Schwab&England ρ=-0,388 
(P=0,031).
Discussion 
NMS are a great burden of almost every PD patient. Never-
theless, they are still poorly recognized and treated. With that 
thought in mind, we ventured in making of this pilot study in 
which the main goals were to show the prevalence of different 
NMS, and the effects of different variables such as duration, 
and stage of disease on NMS. One of the reasons NMS are not 
getting the recognition they deserve is because patients often 
find it uncomfortable to talk about them, or they think of the 
symptoms as part of aging. In our study, we witnessed that some 
of our patients had difficulty scoring symptoms such as sexual 
function, hallucinations, etc. Our observation is confirmed by a 
study done by K.Ray Chaudhuri et al. 4 who established that in 
average 4 NMS per patient are not told off to the physician. In 
our study, all patients reported at least one NMS which is per 
other studies in which at least one NMS was prevalent in 97,6% 
5, 98,4%(6), and 99,3% 7 patients. On average 12 different 
NMS were reported per patient in our study which is close to an 
average of 10 NMS reported in previous studies 5,6. An average 
number of 12 NMS signifies a severe stage of disease accord-
ing to criteria for grading of NMSQuest results established in 
research done by K. Ray Chaudhuri et al 8. Individually most 
prevalent NMS were autonomic symptoms such as nocturia 
(67,74%), urgency (61,29%), constipation (61,29%), intense 
dreams (58,06%) and forgetfulness (58,06%). These results are 
mostly following a much larger study done by Pablo Martinez 
Martin et al. 6, in which most prevalent NMS were nocturia 
(61,90%), urgency (55,81%), constipation (52,48%), depression 
(50,10%), and forgetfulness (44,85%). A study done by Praween 
Lolekh et al. 9 also shows a great prevalence of urinary symptoms 
(nocturia 79,1% and urgency 73%). The least prevalent NMS in 
our study were delusions (6,45%), hallucinations (16,12%), and 
day time sleepiness (25,80%). Prevalence of delusions and hal-
lucinations is rare, and usually is present in patients in which the 
duration of the disease is longer, they are in advanced age, have a 
poor cognitive reserve, and use a larger dosage of dopaminergic 
drugs. Concerning hallucinations and delusions our results are 
following other studies 6,9, even thou some of the symptoms such 
as incontinence are even less prevalent.
We found that there was no statistically significant difference be-
tween the total number of NMS between men and women, and 
these results are mostly in accordance with previous studies 5,6,10,11 
which also report non-significant differences. Then again study 
done by Martinez Martin et al. 11 went into a deeper analysis of 
differences between male and female PD patients. They found 
that women are more likely to report tiredness, anxiety, depres-
sion, constipation, restless legs, and pain, while men are more 
likely to report day time sleepiness, dribbling, change in sex 
drive, and problems with sexual function. 
Our study shows that the age at which diagnosis is made and 
age during an examination of patients did not correlate with the 
total number of NMS. Contrary to that, the duration of disease 
showed a significant effect on the total number of NMS telling 
us that with the longer duration of the disease the burden of 
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NMS grows ever larger. Those findings are following previous 
research 5,6,10,12. In between specific domains we found that the 
number of symptoms of depression, anxiety, and miscellaneous 
significantly rises with the longer duration of disease. We explain 
that with a longer duration of disease a combination of disease 
pathophysiology and patient’s psychological mechanisms crum-
bling, due to losing hope in treatment possibilities, gives rise to 
more depression and anxiety being prevalent with such patients. 
Symptoms of miscellaneous domain rise with longer duration of 
disease as side effects of therapy mount up, and symptoms such 
as unexplained pain, and weight change can be caused by more 
often on-off periods causing rigor and gastroparesis in longer-
lasting disease. Also, these findings are following a larger multi-
center study done by M.A Hely et al. 13 in which they discovered 
that non-L-dopa symptoms such as depression, anxiety, falling, 
etc. dominate with longer duration of disease. A much larger 
study done by Paolo Barone et al. 14 showed conflicting results 
putting depression and other psychiatric symptoms in a group 
of those NMS which were unaffected with longer duration of 
disease. The difference could be explained by our smaller sample 
of patients, and differences in cultures of examined patients. We 
found that patients which had digestive symptoms more often 
complained on urinary (ρ=0,356; P=0,049), cognitive (ρ=0,457; 
P=0,010), sleeping (ρ=0,638; P<0,001), hallucination (ρ=0,412; 
P=0,021), and miscellaneous symptoms (ρ=0,621; P<0,001). 
Those patients that reported cognitive symptoms more often 
reported sexual dysfunction (ρ=0,383; P=0,034), hallucinations 
(ρ=0,466; P=0,008) and miscellaneous symptoms (ρ=0,363; 
P=0,045). These findings can be explained by the neuropatho-
logical progress of PD. Because digestive symptoms such as con-
stipation, dribbling, and incomplete bowel emptying represent 
symptoms which are present in Braak stages 1 thru 6 15, with 
pathology happening from the dorsal motor nerve of Vagus, and 
to gastroesophageal plexus to sympathetic and parasympathetic 
ganglia it poses no surprise that they are present with all other 
symptoms that encompass different Braak stages of neuropathol-
ogy, meaning that digestive symptoms are a common denomina-
tor in all stages of PD 16. Cognitive symptoms of PD represent 
the last stage of disease progression together with hallucinations, 
sexual dysfunction, unexplained pain, and falling. These symp-
toms represent Braak stages 4 to 6 of αSyn pathology 15,16. There 
have been numerous studies that proved both epidemiological 
and neuroimaging association between cognitive symptoms and 
hallucinations 17,18,19,20 A study done by Pablo Martinez Martin et 
al 6 found a correlation only among depression/anxiety domain 
with a urinary and cognitive domain.
NMS are present in all stages of the disease. Our findings of cor-
relation of the total number of NMS with disease stage according 
to Hoehn&Yahr are following numerous other studies 5-7,21-23. 
We found that patients of the moderate and severe stage had 
significantly higher NMS burden than patients in the mild stage 
of the disease. What is specific for our pilot study is that patients 
in a moderate stage of the disease reported the highest number of 
NMS. We try to explain it with the fact that patients in the mod-
erate stage still have their motor symptoms adequately compen-
sated and thus their focus is on NMS which are harder to control 
with pharmacotherapy. Compared to them the focus of patients 
in the severe stage of the disease is on more severe motor symp-
toms which come with disease progression, while simultaneously 
they ignore some of the NMS as not connected to PD. 
Other research shows a continuous rise in NMS number to-
gether with the stage of disease in which patients in the severe 
stage have the highest number of NMS 5-8,9. Once again our 
small sample may be a confounding factor, also the prevailing 
culture among examined patients gives primary focus on motor 
symptoms which prevents them from doing daily activities. 
According to Hoehn&Yahr stage patients in the mild stage were 
most troubled by urinary (47%), cognitive (37%), and diges-
tive symptoms (34%). Patients in the moderate stage were most 
troubled by urinary (90%), digestive (70%), and cardiovascular 
symptoms (70%), while patients in the severe stage were most 
troubled by urinary (83%), cardiovascular (83%) and depression 
and anxiety symptoms (67%). With the average age of patients 
being 70 years it comes with no surprise that patients in the 
mild stage of disease complain about cognitive symptoms. These 
results are following Braak et al. 15 hypothesis of disease patho-
physiology. We found that all questionnaires used had significant 
correlations among themselves and with the duration of disease. 
It means that with a longer duration of disease of examined 
patients they had higher UPDRS scores, they were in a higher 
stage of the disease, and their daily activities diminished. Those 
results are in accordance with previous studies 9,12 and show that 
NMSQuest is a reliable source of information not only concern-
ing NMS but also the progress and staging of disease. NMS-
Quest presented itself as a useful way of presenting symptoms 
that concern patients which would otherwise be missed. In a 
modern and all-encompassing approach to PD, it is important 
to direct more attention to NMS and to find an adequate way of 
ameliorating these symptoms. Limitations of our pilot study are 
its small number of participants and focus on only those patients 
treated at University Hospital Center Split. Nevertheless, this 
pilot study confirms the potential in examining NMS symptoms 
of PD on a much broader scale in Croatia.
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